OS Therapies (OSTX) announced that it has scheduled a Scientific Advice Meeting in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway with the United Kingdom’s Medicines and Healthcare products Regulatory Agency for OST-HER2, its immunotherapy candidate for the prevention of recurrence of metastases in osteosarcoma. The company released positive Phase 2b data in January 2025 that demonstrates statistically significant results in the primary endpoint of the study, 12-month event free survival (EFS). The meeting with MHRA has been scheduled to position the company to bring OST-HER2 to market in the UK in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSTX:
Questions or Comments about the article? Write to editor@tipranks.com